Cost of Medications Recommended by Canadian Acne Clinical Practice Guidelines.
BACKGROUND
Acne affects a large proportion of the Canadian population and has psychosocial and financial consequences.


OBJECTIVE
We provide cost information for treatments recommended by the Canadian acne guidelines.


METHODS
Highest level recommendations were selected for 3-month usage cost.


RESULTS
Three-month estimated treatment costs were as follows: topical retinoids ($14.40-$73.80), benzoyl peroxide (BPO; $6.75), fixed-dose BPO-clindamycin ($40.95-$44.10) and BPO-adapalene ($73.80), oral antibiotics ($25.20 for tetracycline 250 mg qid; $52.20 and $52.74 for doxycycline 50 mg bid and 100 mg od, respectively), and hormonal therapy ($26.46-$37.80 for ethinyl estradiol [EE] 0.030 mg/drospirenone 3mg and $75.60-108.99 for EE 0.035 mg/cyproterone acetate 2 mg). Oral isotretinoin 3-month costs ranged from $393.96 to $478.80.


CONCLUSIONS
Awareness of costs of recommended treatments may facilitate improved outcomes by increasing procurement and adherence.
Private practice, Family Medicine, Windsor, ON, Canada.
Tiffany
T
Czilli
Schulich School of Medicine and Dentistry, Windsor Campus, University of Western Ontario, Windsor, ON, Canada jerrytan@wcri.ca.|Windsor Clinical Research, Ontario, Windsor, ON, Canada.
Jerry
J
Tan
Schulich School of Medicine and Dentistry, Windsor Campus, University of Western Ontario, Windsor, ON, Canada.
Sanja
S
Knezevic
Independent pharmacist, Wellington Apothecary, Windsor, ON, Canada.
Colin
C
Peters
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000191:economics*; D000068816:Adapalene / Q000191:economics; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000726:Androgen Antagonists / Q000191:economics; D000736:Androstenes / Q000191:economics; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics*; D001585:Benzoyl Peroxide / Q000191:economics*; D002170:Canada; D002981:Clindamycin / Q000008:administration & dosage / Q000191:economics; D017373:Cyproterone Acetate / Q000191:economics; D003879:Dermatologic Agents / Q000191:economics*; D004318:Doxycycline / Q000008:administration & dosage / Q000191:economics; D004338:Drug Combinations; D004967:Estrogens / Q000191:economics; D004997:Ethinyl Estradiol / Q000191:economics; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000191:economics; D000451:Mineralocorticoid Receptor Antagonists / Q000191:economics; D008911:Minocycline / Q000008:administration & dosage / Q000191:economics; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D013752:Tetracycline / Q000008:administration & dosage / Q000191:economics
D000726:Androgen Antagonists; D000736:Androstenes; D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D000068816:Adapalene; D002981:Clindamycin; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D015474:Isotretinoin; D013752:Tetracycline; D008911:Minocycline; D004318:Doxycycline; C035144:drospirenone; D001585:Benzoyl Peroxide
Canadian; Canadian acne guidelines; acne; cost; cost information; dermatology; drugs; guidelines; medications; recommendations; therapies